Your browser doesn't support javascript.
loading
SARS-CoV-2 variant exposures elicit antibody responses with differential cross-neutralization of established and emerging strains including Delta and Omicron.
Laurie, Matthew T; Liu, Jamin; Sunshine, Sara; Peng, James; Black, Douglas; Mitchell, Anthea M; Mann, Sabrina A; Pilarowski, Genay; Zorn, Kelsey C; Rubio, Luis; Bravo, Sara; Marquez, Carina; Sabatino, Joseph J; Mittl, Kristen; Petersen, Maya; Havlir, Diane; DeRisi, Joseph.
Afiliação
  • Laurie MT; Department of Biochemistry and Biophysics, University of California San Francisco, San Francisco, CA 94143, USA.
  • Liu J; Department of Biochemistry and Biophysics, University of California San Francisco, San Francisco, CA 94143, USA.
  • Sunshine S; University of California Berkeley-University of California San Francisco Graduate Program in Bioengineering, Berkeley, CA 94720, USA.
  • Peng J; Department of Biochemistry and Biophysics, University of California San Francisco, San Francisco, CA 94143, USA.
  • Black D; Department of Medicine, University of California San Francisco, San Francisco, CA 94143, USA.
  • Mitchell AM; Department of Medicine, University of California San Francisco, San Francisco, CA 94143, USA.
  • Mann SA; Department of Biochemistry and Biophysics, University of California San Francisco, San Francisco, CA 94143, USA.
  • Pilarowski G; Chan Zuckerberg Biohub, San Francisco, CA 94158, USA.
  • Zorn KC; Department of Biochemistry and Biophysics, University of California San Francisco, San Francisco, CA 94143, USA.
  • Rubio L; Chan Zuckerberg Biohub, San Francisco, CA 94158, USA.
  • Bravo S; The Public Health Company, Oakland, CA 94610, USA.
  • Marquez C; Unidos en Salud, San Francisco, CA, 94143, USA.
  • Sabatino JJ; Department of Biochemistry and Biophysics, University of California San Francisco, San Francisco, CA 94143, USA.
  • Mittl K; Department of Medicine, University of California San Francisco, San Francisco, CA 94143, USA.
  • Petersen M; Unidos en Salud, San Francisco, CA, 94143, USA.
  • Havlir D; Department of Medicine, University of California San Francisco, San Francisco, CA 94143, USA.
  • DeRisi J; Weill Institute for Neurosciences, Department of Neurology, San Francisco, CA 94158, USA.
medRxiv ; 2021 Dec 22.
Article em En | MEDLINE | ID: mdl-34981075
The wide spectrum of SARS-CoV-2 variants with phenotypes impacting transmission and antibody sensitivity necessitates investigation of the immune response to different spike protein versions. Here, we compare the neutralization of variants of concern, including B.1.617.2 (Delta) and B.1.1.529 (Omicron) in sera from individuals exposed to variant infection, vaccination, or both. We demonstrate that neutralizing antibody responses are strongest against variants sharing certain spike mutations with the immunizing exposure. We also observe that exposure to multiple spike variants increases the breadth of variant cross-neutralization. These findings contribute to understanding relationships between exposures and antibody responses and may inform booster vaccination strategies. SUMMARY: This study characterizes neutralization of eight different SARS-CoV-2 variants, including Delta and Omicron, with respect to nine different prior exposures, including vaccination, booster, and infections with Delta, Epsilon, and others. Different exposures were found to confer substantially differing neutralization specificity.

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: MedRxiv Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: MedRxiv Ano de publicação: 2021 Tipo de documento: Article